Stoke Therapeutics, Inc. (STOK) stock surged +2.24%, trading at $10.02 on NASDAQ, up from the previous close of $9.80. The stock opened at $9.77, fluctuating between $9.66 and $10.43 in the recent session.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Employees | 110 |
Beta | 0.95 |
Sales or Revenue | $8.78M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Stoke Therapeutics, Inc. (NASDAQ: STOK) stock price is $10.02 in the last trading session. During the trading session, STOK stock reached the peak price of $10.43 while $9.66 was the lowest point it dropped to. The percentage change in STOK stock occurred in the recent session was 2.24% while the dollar amount for the price change in STOK stock was $0.22.
The NASDAQ listed STOK is part of Biotechnology industry that operates in the broader Healthcare sector. Stoke Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Shamim Ruff
Chief Regulatory Officer
Dr. Edward M. Kaye M.D., Ph.D.
Chief Executive Officer & Director
Ms. Dawn Kalmar
Chief Communications Officer
Ms. Joan Wood
Chief HR Officer
Dr. Adrian R. Krainer Ph.D.
Co-Founder, Independent Director & Member of Scientific Advisory Board
Mr. Stephen J. Tulipano CPA, CPA, MBA
Chief Financial Officer
Ms. Isabel Aznarez Ph.D.
Co-Founder & Group Vice President of Discovery Research
Dr. Huw M. Nash Ph.D.
Chief Operating Officer & Chief Bus. Officer
Mr. Eric Rojas
Head of Investor Relations
Mr. Jonathan Allan J.D.
Corporation Sec. & Gen. Counsel
STOK's closing price is 139.61% higher than its 52-week low of $4.09 where as its distance from 52-week high of $17.58 is -44.26%.
Number of STOK employees currently stands at 110.
Official Website of STOK is: https://www.stoketherapeutics.com
STOK could be contacted at phone 781 430 8200 and can also be accessed through its website. STOK operates from 45 Wiggins Avenue, Bedford, MA 01730, United States.
STOK stock volume for the day was 562.64K shares. The average number of STOK shares traded daily for last 3 months was 664.08K.
The market value of STOK currently stands at $530.73M with its latest stock price at $10.02 and 52.97M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com